Top Story

Survivors of osteosarcoma at increased risk for second malignant neoplasms

August 28, 2014

Survivors of osteosarcoma demonstrated an increased risk for second malignant neoplasms, and the risk persisted long after the conclusion of osteosarcoma treatment, according to study results.

Researchers also observed elevated risks among patients treated in more recent time periods.

In the Journals

Tumor size, location, grade predicted late recurrence in soft tissue sarcoma

August 6, 2014
Late recurrence in most patients treated for soft tissue sarcoma is uncommon, according to study results.However, the findings suggest long-term follow-up is necessary…
FDA News

FDA accepts first application for biosimilar filgrastim

July 28, 2014
Sandoz Inc. recently announced that the FDA has accepted its Biologics License Application for filgrastim, which was filed under the new biosimilar pathway created in…
In the Journals

Time to diagnosis not associated with survival in adolescents with Ewing tumors

June 27, 2014
The time to diagnosis of Ewing tumors was long and did not improve over time, but it did not appear to affect survival, surgical outcome or metastasis, according to…
CME CNE

Treatment Decision-Making through the Spectrum of MDS: Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

8/20/2014
MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
CME CNE

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

8/20/2014
MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »

Filter By:

In the Journals

Survivors of osteosarcoma at increased risk for second malignant neoplasms

August 28, 2014
Survivors of osteosarcoma demonstrated an increased risk for second malignant neoplasms, and the risk persisted long after the conclusion of…
In the Journals

Tumor size, location, grade predicted late recurrence in soft tissue sarcoma

August 6, 2014
Late recurrence in most patients treated for soft tissue sarcoma is uncommon, according to study results.However, the findings suggest long-term…
FDA News

FDA accepts first application for biosimilar filgrastim

July 28, 2014
Sandoz Inc. recently announced that the FDA has accepted its Biologics License Application for filgrastim, which was filed under the new biosimilar…
In the Journals

Time to diagnosis not associated with survival in adolescents with Ewing tumors

June 27, 2014
The time to diagnosis of Ewing tumors was long and did not improve over time, but it did not appear to affect survival, surgical outcome or…

Top 8 lessons learned at ASCO 2014

June 25, 2014
The theme of this year’s ASCO Annual Meeting, “Science and Society,” emphasized patient-centered focus — looking at the full…
Perspective

Temsirolimus combination improved event-free survival in rhabdomyosarcoma

June 1, 2014
There are about 400 new cases of rhabdomyosarcoma diagnosed in children younger than 19 years in this country every year. Part of the clinical…
Meeting News Coverage Perspective

Risk-based strategy outlines new approach to treatment in pediatric soft tissue sarcomas

June 1, 2014
CHICAGO — A risk-based treatment strategy categorized pediatric patients with nonrhabdomyosarcoma soft tissue sarcomas into distinct prognostic…
In the Journals

Surgical resection of extremity tumors after chemotherapy brings better results

May 27, 2014
Surgical resection of a primary tumor in the extremities following neoadjuvant chemotherapy leads to more positive results, according to recently…
In the Journals

Area poverty rate linked to incidence of certain cancers

May 27, 2014
Incidence of certain cancers in specific neighborhoods varied considerably based on the area’s poverty level, according to study results.Areas…
Meeting News Coverage Perspective

Novel small-molecule inhibitor shows promise for pigmented villonodular synovitis

May 14, 2014
The novel oral tyrosine kinase inhibitor PLX3397 induced tumor shrinkage and stable disease in patients with recurrent pigmented villonodular…
More Headlines »